Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 5

Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

,

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.